Myasthenia gravis following the initiation of statin therapy: A multinational self‐controlled case series study
In this multinational SCCS study, statin initiation may be associated with increased risk of new-onset MG during the first 6-12 months, with greater magnitude of risk elevation for higher intensity statin therapy. Consideration of the possibility of new-onset MG may be advisable within first 6-12 months after initiating statins, especially for medium-to-high-intensity statin therapy.
Authors
- Celine Sze Ling Chui (ORCID: https://orcid.org/0000-0003-1513-8726)
- Wanchun Xu (ORCID: https://orcid.org/0000-0002-6183-571X)
- Eric Yuk Fai Wan (ORCID: https://orcid.org/0000-0002-6275-1147)
- Rie Masuda
- Jing Wei Neo (ORCID: https://orcid.org/0000-0002-4075-892X)
- Gary K. K. Lau
- Yuta Taniguchi (ORCID: https://orcid.org/0000-0002-0176-2379)
- Vincent Ka Chun Yan (ORCID: https://orcid.org/0000-0001-5225-3032)
- Sreemanee Raaj Dorajoo (ORCID: https://orcid.org/0000-0002-9613-6994)
- Xue Li (ORCID: https://orcid.org/0000-0002-8313-3671)
- Masao Iwagami (ORCID: https://orcid.org/0000-0001-8983-8958)
- Koon Ho Chan
- Ian Chi Kei Wong
- Nanako Tamiya
- Kwun Kei Fung
- Esther Wai Yin Chan
- Francisco Tsz Tsun Lai
Institutions
- Macau University of Science and Technology (MO)
- University of Tsukuba (JP)
- Aston University (GB)
- Health Sciences Authority (SG)
- Tokyo Health Care University (JP)
- City University of Hong Kong, Shenzhen Research Institute (CN)
- Institut de Recherche et d’Innovation (FR)
- Nano and Advanced Materials Institute (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Journal of Internal Medicine
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1111/joim.70072
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Innovation and Technology Commission
- Health and Medical Research Fund